Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab pediatric phase 3 study in moderate-to-severe atopic dermatitis
jRCT2031220533Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Investigator Global Assessment response and EASI-75 response. Started Mar 2023; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031220533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220533.